[0:a] atrim=start=0:end=53.07 [t0a]; [t0a]concat=n=1:v=0:a=1[a]; color=#FCF3ED:size=768x768,format=yuva420p,trim=start=0:end=53.07[bg];[bg]subtitles='/imagecap/temp/010000002752ea21ef0c08de1becba19.ass':fontsdir=/google-fonts/rajdhani:force_style='Fontname=Rajdhani'[vbgsub]; color=white:size=400x400,format=yuva444p,geq=lum='p(X,Y)':a='st(1,pow(min(W/2,H/2),2))+st(3,pow(X-(W/2),2)+pow(Y-(H/2),2));if(between(ld(3),ld(1)*0.9,ld(1)),255*(1-X/W),0)',drawbox=color=#FF8432:t=fill[frameS];[frameS]scale=140:140,rotate=(2*PI*t):c=none[nimbus];[nimbus]split=1[nimbus3];color=#FCF3ED:size=648x147,format=yuva420p,drawtext=text='Ivana Lisec':fontfile='assets/Rajdhani-Regular.ttf':fontcolor=#FF8432:fontsize=30:x=0:y=25:expansion=none,drawtext=text='Vice President / Business Unit Lead,':fontfile='assets/Rajdhani-Bold.ttf':fontcolor=#FF8432:fontsize=30:x=0:y=60:expansion=none,drawtext=text='Biosimilars and Generics & Vaccines':fontfile='assets/Rajdhani-Bold.ttf':fontcolor=#FF8432:fontsize=30:x=0:y=87:expansion=none[bgSpk3];[1:v]scale=400:400:force_original_aspect_ratio=1,pad=400:400:(ow-iw)/2:(oh-ih)/2:color=white,setsar=1:1,split=2[whiteCanvas][scaleSrc];color=c=black@0:s=400x400[blackBackground];[whiteCanvas]scale=w=iw*2:h=iw*2,format=yuva444p,geq=lum='p(X,Y)':a='st(1,pow(min(W/2,H/2),2))+st(3,pow(X-(W/2),2)+pow(Y-(H/2),2));if(lte(ld(3),ld(1)),255,0)',drawbox=color=white@1:t=fill,scale=w=iw/2:h=iw/2[whiteCircle];[blackBackground][whiteCircle]overlay[alphaMask];[scaleSrc][alphaMask]alphamerge,scale=100:100[spkPhoto3];[bgSpk3][spkPhoto3]overlay=x=(548-20):y=(0+20):shortest=0[spkBgPhoto3];[spkBgPhoto3][nimbus3]overlay=x=(508):y=(0):shortest=1[spk_3];[spk_3]split=1[spk_30];[spk_30]fade=in:st=0:d=1:alpha=1,fade=t=out:st=52.07:d=1:alpha=1[fade_03];[vbgsub][fade_03]overlay=enable='between=(t,0,53.07)':x=60:y=(H-h-60):shortest=1[vspkbg];